Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2025.112204 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Aurora Callahan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI 02903, USA. Hauptthemen laut MEDLINE: Signal Transduction, Proteomics, Receptors, Antigen, T-Cell, Antigens, CD19. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Although chimeric antigen receptor (CAR) T cell therapy has revolutionised individualised cancer therapies for relapsed/refractory lymphomas, low long-term retention due to basal signalling (antigen-independent activation in the absence of cognate antigen) and off-target toxicity limit the broad applicability of CAR-T products. During CAR development, researchers use model systems, like Jurkat T cells (Jurkats), to screen intracellular signalling arrangements based on their ability to activate (e.g., CD69 expression) and withstand repeated antigen encounters. Although Jurkats are standard for CAR screening, the mapping of CAR generations to Jurkat-specific pTyr networks relative to key TCR nodes and CD69 readouts is not well defined, blurring how hierarchical signalling drives activation. Here, we investigated how costimulation influenced tyrosine phosphorylation cascades using LC-MS/MS based phosphotyrosine (pY) proteomics and CD69 expression in the presence of small molecule inhibitors of key TCR signalling regulators. We found that including TCRζ (CD3ζ; gene CD247) in first (ζ-CAR), second (28ζ-CAR and BBζ-CAR), and third (28BBζ-CAR) generation CARs largely determined pY signalling, irrespective of costimulation. Further, we showed that the phosphatase activity of PTPN22 and SHP-1 were largely negligible for activation of CARs, but indiscriminate inhibition of phosphatases using pervanadate (PV) selectively activated BBζ-CARs without antigen encounter. Finally, we found that selective, partial inhibition of Itk using Soquelitinib reduced basal CD69 expression in CAR-Jurkat cells while maintaining their ability to activate in response to antigen. These data suggest that TCRζ determines the pY signalling profile and that Itk drives basal activation of CD19-CAR Jurkats, which may impact evaluation of new CAR designs in CAR-Jurkat screens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI 02903, USA.
- Department of Cell Biology, Yale School of Medicine, Yale University, New Haven, CT 06520, USA.
- Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI 02903, USA. Electronic address: art@drsalomon.com.
Förderung
- NIAID NIH HHS
- NIH HHS
- NCI NIH HHS
- NIGMS NIH HHS
- NIBIB NIH HHS
- Human Frontier Science Program
- Gabrielle's Angel Foundation for Cancer Research
- National Institutes of Health
Zitieren
APA
Callahan, A., Puterbaugh, R. Z., Ro, T., Zhang, X., Su, X., & Salomon, A. R. (2026). Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112204
Vancouver
Callahan A, Puterbaugh RZ, Ro T, Zhang X, Su X, Salomon AR. Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2025.112204
BibTeX
@article{Callahan2026,
author = {Callahan, Aurora and Puterbaugh, Ryan Z and Ro, Timothy and Zhang, Xinyan and Su, Xiaolei and Salomon, Arthur R},
title = {Phosphoproteomic analysis of successive Jurkat CD19-CAR generations reveals TCRζ-driven signalling},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2025.112204}
}
EUVIMED